Jeff Jones
Stock Analyst at Oppenheimer
(3.75)
# 711
Out of 5,131 analysts
99
Total ratings
28.09%
Success rate
17.67%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Outperform | $57 → $60 | $20.58 | +191.56% | 3 | Jan 26, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $15 → $32 | $18.66 | +71.49% | 6 | Jan 21, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Perform | n/a | $13.97 | - | 12 | Jan 8, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $82.34 | +45.74% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.51 | +1,555.63% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $7.56 | +601.06% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $22.46 | +95.90% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $26.54 | -5.80% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $6.08 | +179.61% | 4 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.28 | +166.42% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $2.79 | +545.16% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.29 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $4.70 | +240.43% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.11 | +3,954.05% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.47 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.07 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.78 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.11 | +1,251.35% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $4.34 | +43,102.76% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.33 | +32,933.03% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Jan 26, 2026
Maintains: Outperform
Price Target: $57 → $60
Current: $20.58
Upside: +191.56%
Corvus Pharmaceuticals
Jan 21, 2026
Maintains: Outperform
Price Target: $15 → $32
Current: $18.66
Upside: +71.49%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Perform
Price Target: n/a
Current: $13.97
Upside: -
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $82.34
Upside: +45.74%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.51
Upside: +1,555.63%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $7.56
Upside: +601.06%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $22.46
Upside: +95.90%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $26.54
Upside: -5.80%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $6.08
Upside: +179.61%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.28
Upside: +166.42%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $2.79
Upside: +545.16%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.29
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $4.70
Upside: +240.43%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.11
Upside: +3,954.05%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.47
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.07
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.78
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.11
Upside: +1,251.35%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $4.34
Upside: +43,102.76%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.33
Upside: +32,933.03%